Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcano's VH® IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
|
|
VH® IVUS
Image |
|
September 24, 2009 --
San Francisco -- Volcano Corporation
(Nasdaq: VOLC), a leader in the development, manufacturing
and sales of products for the diagnosis and treatment
of coronary and peripheral artery disease, announced today imaging
results from PROSPECT, the landmark 700 patient natural history
study sponsored by Abbott and co-funded by Volcano.These data demonstrate
the progression of cardiovascular disease via precise, intravascular
imaging, and the ability of Volcano's
proprietary VHŽ IVUS technology to be used to classify lesions by
plaque "type" per the PROSPECT protocol and to assess the risk of
each plaque type to cause an event, or to remain stable out to three
years. |
PROSPECT results presented today include the landmark finding
that angiographically mild lesions with certain morphologic features
on grayscale and VH IVUS present with a 3 year cardiac event rate
of 17%, versus other morphologies (indistinguishable by conventional
angiograms) with three year event risks of less than 1%.
"For years, interventional cardiologists have been focused on using angiography
to identify blockages and to restore flow. PROSPECT teaches us that looking at
the angiographic severity of the blockage is not enough, and we must understand
the type of disease present in the vessel wall," said Gregg Stone, MD, of Columbia
University Medical Center and Principal Investigator of PROSPECT. "With VH®
IVUS we can clearly see two things: one, that "mild" lesions on angiography
are capable of progressing quickly into events for the patient: and two, events
also
take place in locations of severe disease that are often missed by angiography.
Understanding the risk of each lesion type is paramount to minimizing the occurrence
of these future events. Current practice using angiography guidance alone is
insufficient in that regard."
PROSPECT (Providing Regional Observations to Study Predictors of Events in the
Coronary Tree) is a first-of-its-kind multi-center, natural history study of
acute coronary syndrome (ACS) patients. These patients underwent PCI to restore
blood flow at baseline. Following the PCI procedure, an angiogram and a detailed
IVUS image was captured in the three primary coronary arteries before the patient
was sent home. If the patient had a subsequent event, they were readmitted, and
again, an angiogram and IVUS imaging was performed. The core laboratory (Cardiovascular
Research Foundation, New York, NY) then matched the location of the secondary
event to the initial IVUS images to determine which locations progressed, and
which lesions remained stable. Patient follow-up continued for three years.
"Angiography alone is not enough and more and more clinical data continues to
support that conclusion," said Scott Huennekens, President and CEO of Volcano. "PROSPECT
has shown that not all coronary disease is the same. We cannot predict a patient's
risk of having future cardiac events by looking at a 2-D, black-and-white image
of the arterial lumen. Available tools like IVUS and VH® IVUS that look at
the quantity, location and type of disease and not just the narrowing of the
vessel improve our ability to determine the likelihood of a particular lesion
type to cause an event. PROSPECT has shown the ability to use VH and grayscale
IVUS to classify different lesion types per the PROSPECT definitions. This trial
highlights not only the potential of Volcano's VH® IVUS, but just as important,
the limitations of using angiography alone."
VH® IVUS uses advanced spectral analysis of the ultrasound signal to classify
atherosclerotic disease into different plaque components. By using these four
plaque components, the PROSPECT investigators grouped the baseline lesions into
five distinct lesion types; Fibrotic, Fibro-Calcific, Pathological Intimal Thickening,
Thick-Cap Fibroatheroma and Thin-Cap Fibroatheroma, in order of hypothesized
risk.
PROSPECT Results
The PROSPECT event data presented today demonstrates that the measurements made
using grayscale and VH® IVUS did have a statistically significant impact in
determining the likelihood of a particular lesion type to cause an event. The
highest risk PROSPECT plaque type being VH Thin Cap Fibroatheromas with a minimum
lumen area of less than or equal to 4mm(2) and a plaque burden greater than or
equal to 70%. All three of these important parameters (each an independent predictor)
when combined showed that the particular lesion imaged at baseline had a 17.2%
chance of causing an event within three years. It is important to note that current
practice of using angiography alone cannot measure plaque burden or the presence
of VH-TCFAs, which were the two most significant predictors of lesion risk in
the study. These measures can only be collected using Volcano's proprietary Eagle
Eye Gold IVUS catheter not only visualizes and measures plaque burden but also
collects signals for VH imaging allowing display of four plaque components.
Importantly, the absence of a fibroatheroma by PROSPECT definitions in imaged
lesions was a strong predictor of lesion stability over three years as shown
in the graph below. In lesions defined by PROSPECT having less than 10% Necrotic
Core (red on VH IVUS), the likelihood of that lesion progressing to an event
over three year was negligible, independent of other grayscale and angiographic
factors.
It is widely believed that a hazard ratio of
greater than 2.0 is a clinically meaningful predictor of an event.
You can see from the chart below that the hazard
ratio for a PROSPECT defined VH-TCFA is 3.8 with a p-value of < 0.0001 indicating
a positive predictive value of causing an event that is statistically significant.
The converse is true for PIT lesions which have a hazard ratio of only 0.2, indicating
low likelihood of causing an event, which is also statistically significant.
"Healthcare reform has reached a boiling point," continued Huennekens. "The
power of this study is quite simple: Angiography alone is not enough
and we need more
precise, targeted procedures. PROSPECT is not only important for identifying
high-risk plaques so they can be treated to prevent future events. The findings
are arguably just as important because they identify low-risk plaques, which
do not need intervention which can decrease costs and future events. VH® IVUS
is very different from non-invasive imaging technologies like CT and MRI, which
have been accused of funneling too many procedures to the cath lab. In the case
of IVUS, these patients are already in the cath lab, and are already getting
an intervention. This tool simply allows physicians to further triage which lesions
need to be stented, and which lesions can be treated with medical therapy. The
negative predictive accuracy of VH® IVUS is very similar to Fractional Flow
Reserve (FFR) in its potential to reduce procedure costs by stenting only the
patients and lesions that will benefit from that therapy."
Evening Symposium
To explore the imaging data in greater detail, Volcano will host an
evening symposium
entitled, "Imaging Matters! Identifying high risk patients and optimizing PCI." The
symposium will include late breaking results from PROSPECT, FAME and other clinical
studies. The first session of the symposium, entitled, "Can imaging help identify
at-risk vulnerable plaques and patients before catastrophe (or those not at risk)," will
feature presentations from Patrick W. Serruys, M.D., Gary S. Mintz, M.D., Gregg
W. Stone, M.D. and Alexandra Lansky, M.D. The second session, entitled, "Ischemia,
FFR and Optimal Revascularization," will include presentations by Gregg W. Stone,
M.D., Bernard de Bruyne, M.D., PhD, Bill Fearon, M.D. and Mort Kern, M.D. The
event will be held at the Hilton San Francisco in the Imperial Room on Thursday,
September 24. A reception will be held from 7:00 PM - 8:00 PM, followed by the
symposium from 8:00 PM - 10:00 PM.
About the PROSPECT Trial
Abbott's PROSPECT trial is the first prospective natural history study to examine
the role of vulnerable plaque and how it might progress to a cardiac event. PROSPECT
used novel intravascular imaging technology to correlate plaque characteristics,
patient risk factors and biomarker measurements with subsequent heart attacks
and other cardiac events, potentially paving the way for physicians to identify
and treat at-risk patients before a heart attack occurs.
PROSPECT enrolled 700 patients from 40 clinical centers across the United States
and Europe. All patients received PCI for acute coronary syndrome (ACS), which
included unstable angina, NSTEMI or STEMI. Patient follow up continued for three
years. Abbott sponsored the study and VH® IVUS imaging technology was provided
by Volcano Corporation.
About Volcano Corporation
Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to
facilitate endovascular procedures, enhance the diagnosis of vascular and structural
heart disease and guide optimal therapies. The company's intravascular ultrasound
(IVUS) product line includes ultrasound consoles that can be integrated directly
into virtually any modern cath lab. Volcano IVUS offers unique features, including
both single-use phased array and rotational IVUS imaging catheters, and advanced
functionality options, such as VH®) IVUS tissue characterization and ChromaFlo®.
Volcano also provides functional measurement (FM) consoles and single-use pressure
and flow guide wires and is developing a line of ultra-high resolution Optical
Coherence Tomography (OCT) and Forward-Looking IVUS systems and catheters. Currently,
more than 4,400 Volcano IVUS and FM systems are installed worldwide, and more
than half of Volcano's revenues are derived from outside the United States. Through
its wholly-owned subsidiary, Axsun Technologies, Volcano also develops and manufactures
optical monitors, lasers and optical engines used in telecommunications, spectroscopy
and other industrial applications. These products are sold to a variety of customers,
including Nokia Siemens, Ericsson, Alcatel-Lucent and HuaWei Technologies. For
more information, visit the company's website at http://www.volcanocorp.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Any statements
in
this release regarding Volcano's business that are not historical facts may be
considered "forward-looking statements," including statements regarding the potential
benefits of the procedures described above and of the Company's products, results
and implications of the data from the PROSPECT trial and market adoption of the
company's technology, the impact of clinical and other technical data. Forward-looking
statements are based on management's current preliminary expectations and are
subject to risks and uncertainties, which may cause Volcano's results to differ
materially and adversely from the statements contained herein. Some of the potential
risks and uncertainties that could cause actual results to differ from the results
predicted are detailed in the company's annual report on Form 10-K, quarterly
reports on Form 10-Q and other filings made with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking statements,
which speak only as of the date they are made. Volcano undertakes no obligation
to update any forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence of unanticipated
events.
Source: Volcano
Corporation
|